Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients

Cellular and Molecular Immunology

Volumn 12, Issue 3, 2015, Pages 309-316

  Xu, Xiangsheng ^a,b   Shang, Qinghua ^c   Chen, Xinyue ^d   Nie, Weimin ^b   Zou, Zhengsheng ^b   Huang, Ang ^b   Meng, Ming ^e   Jin, Lei ^b   Xu, Ruonan ^b   Zhang, Ji Yuan ^b   Fu, Junliang ^b   Wang, Lifeng ^b   Tang, Zirong ^b   Xie, Yunbo ^b   Yang, Xiaoming ^a   Zhang, Zheng ^b   Wang, Fu Sheng ^b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b BEIJING 302 HOSPITAL   (China)

^c 88th Hospital of PLA   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e HEBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD40 LIGAND; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NUCLEOSIDE ANALOG; B7 ANTIGEN; CD40 ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE ACTIVATION; IMMUNE CLEARANCE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE HYPERACTIVATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SEROCONVERSION; VIROLOGY; BLOOD; CHRONIC HEPATITIS B; DISEASE COURSE; HEPATITIS B VIRUS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; VIRUS LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, VIRAL; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SEROCONVERSION; VIRAL LOAD; YOUNG ADULT;

EID: 84928887900     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.25     Document Type: Article

References (36)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
2. Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3: 499-512.
3. Schurich A, Khanna P, Lopes AR et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53: 1494-1503.
4. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2011; 61: 1754-1764. doi:10.1136/ gutjnl-2011-301073.
5. Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatology 2012; 27: 223-230.
6. Lo CM, Fung JT, Lau GK et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37: 36-43.
7. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J. Identification of hepatitisBvirus-specific lymphocytes in human liver grafts from HBVimmune donors. Liver Transpl 2007; 13: 71-79.
8. Dahmen U, Li J, Dirsch O et al. Adoptive transfer of donor-derived immunity by liver transplantation: a potential avenue to prevent hepatitis B virus reinfection. J Viral Hepat 2003; 10: 31-36.
9. Schumann A, Lindemann M, Valentin-Gamazo C et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009; 87: 103-111.
10. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
11. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
12. Niscola P, Del Principe MI, Maurillo L et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840-1841.
13. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
14. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91: 2586-2595.
15. Bocher WO, Herzog-Hauff S, Herr W et al. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1996; 105: 52-58.
16. Oliviero B, Cerino A, Varchetta S et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 2011; 55: 53-60.
17. Dusheiko GM, Hoofnagle JH, Cooksley WG, James SP, Jones EA. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest 1983; 71: 1104-1113.
18. Barnaba V, Valesini G, Levrero M et al. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 1985; 60: 259-266.
19. Barnaba V, Levrero M, Ruberti G et al. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. Clin Exp Immunol 1987; 70: 283-288.
20. Zhang Z, Xu X, Lu J et al. B and T lymphocyte attenuator downregulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J Infect Dis 2011; 203: 1668-1678.
21. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008; 122: 12-19.
22. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-245.
23. Chu CM, Sheen IS, Yeh CT, Hsieh SY, Tsai SL, Liaw YF. Serum levels of interferon-Alpha and-gamma in acute and chronic hepatitis B virus infection. Dig Dis Sci 1995; 40: 2107-2112.
24. Gora-Gebka M, Liberek A, Szydlowska-Lysiak W, Bako W, Korzon M. Serum interleukin 6 and interleukin 12 levels in children with chronic hepatitis HBV treated with interferon alpha. Ann Hepatol 2003; 2: 92-97.
25. Zhang Z, Zou ZS, Fu JL et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 2008; 49: 396-406.
26. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol2007; 25: 71-99.
27. Moir S, Ho J, Malaspina A et al. Evidence for HIV-Associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals. J Exp Med 2008; 205: 1797-1805.
28. Wu C, Liu Y, Zhao Q et al. Soluble CD40 ligand-Activated human peripheral B cells as surrogated antigen presenting cells: a preliminary approach for anti-HBV immunotherapy. Virol J 2010; 7: 370.
29. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
30. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105: 1141-1151.
31. Chang JJ, Wightman F, Bartholomeusz A et al. Reduced hepatitis B virus (HBV)-specific CD41 T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBVactive antiretroviral therapy. J Virol 2005; 79: 3038-3051.
32. Maini MK, Boni C, Lee CK et al. The role of virus-specific CD8(1) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
33. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971.
34. Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol2007; 178: 6634-6641.
35. Jaroszewicz J, Calle SB, Wursthorn K et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
36. Nguyen T, Thompson AJ, Bowden S et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.